Lucy M Almers1, James E Graham2, Peter J Havel2, Douglas A Corley3. 1. Division of Research, Kaiser Permanente, Oakland, California. 2. Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, California; Department of Nutrition, University of California, Davis, California. 3. Division of Research, Kaiser Permanente, Oakland, California. Electronic address: Douglas.Corley@kp.org.
Abstract
BACKGROUND & AIMS: Abdominal obesity and increasing body mass index are risk factors for esophageal adenocarcinoma and its main precursor, Barrett's esophagus; however, there are no known biological mechanisms for these associations or regarding why only some patients with gastroesophageal reflux disease develop Barrett's esophagus. We evaluated the association between Barrett's esophagus and multimers of an adipose-associated hormone, adiponectin. METHODS: We conducted a case-control study evaluating the associations between adiponectin (total, high-molecular-weight, and low-/medium-molecular-weight) and Barrett's esophagus within the Kaiser Permanente Northern California population. Patients with a new diagnosis of Barrett's esophagus (cases) were matched to patients with gastroesophageal reflux disease (GERD) without Barrett's esophagus and to population controls. RESULTS: Complete serologic and epidemiologic data were available for 284 cases, 294 GERD controls, and 285 population controls. Increasing adiponectin levels were a risk factor for Barrett's esophagus among patients with GERD (total adiponectin fourth vs first quartile odds ratio [OR], 1.96; 95% confidence interval [CI], 1.17-3.27; high-molecular-weight adiponectin OR, 1.65; 95% CI, 1.00-2.73; low-/medium-molecular-weight adiponectin OR, 2.18; 95% CI, 1.33-3.56), but not compared with population controls. The associations were significantly stronger among patients reporting frequent GERD symptoms and among smokers (P values interaction < .01). CONCLUSIONS: Adiponectin levels are associated positively with the risk of Barrett's esophagus among patients with GERD and among smokers, but not among population controls without GERD symptoms. Higher adiponectin concentrations either independently may contribute to the aberrant healing of esophageal injury into Barrett's esophagus or be a marker for other factors.
BACKGROUND & AIMS:Abdominal obesity and increasing body mass index are risk factors for esophageal adenocarcinoma and its main precursor, Barrett's esophagus; however, there are no known biological mechanisms for these associations or regarding why only some patients with gastroesophageal reflux disease develop Barrett's esophagus. We evaluated the association between Barrett's esophagus and multimers of an adipose-associated hormone, adiponectin. METHODS: We conducted a case-control study evaluating the associations between adiponectin (total, high-molecular-weight, and low-/medium-molecular-weight) and Barrett's esophagus within the Kaiser Permanente Northern California population. Patients with a new diagnosis of Barrett's esophagus (cases) were matched to patients with gastroesophageal reflux disease (GERD) without Barrett's esophagus and to population controls. RESULTS: Complete serologic and epidemiologic data were available for 284 cases, 294 GERD controls, and 285 population controls. Increasing adiponectin levels were a risk factor for Barrett's esophagus among patients with GERD (total adiponectin fourth vs first quartile odds ratio [OR], 1.96; 95% confidence interval [CI], 1.17-3.27; high-molecular-weight adiponectin OR, 1.65; 95% CI, 1.00-2.73; low-/medium-molecular-weight adiponectin OR, 2.18; 95% CI, 1.33-3.56), but not compared with population controls. The associations were significantly stronger among patients reporting frequent GERD symptoms and among smokers (P values interaction < .01). CONCLUSIONS:Adiponectin levels are associated positively with the risk of Barrett's esophagus among patients with GERD and among smokers, but not among population controls without GERD symptoms. Higher adiponectin concentrations either independently may contribute to the aberrant healing of esophageal injury into Barrett's esophagus or be a marker for other factors.
Authors: Jose M Garcia; Andres E Splenser; Jennifer Kramer; Abeer Alsarraj; Stephanie Fitzgerald; David Ramsey; Hashem B El-Serag Journal: Clin Gastroenterol Hepatol Date: 2013-08-15 Impact factor: 11.382
Authors: Y Zhao; R P Ellis; A S Ash; D Calabrese; J Z Ayanian; J P Slaughter; L Weyuker; B Bowen Journal: Health Serv Res Date: 2001-12 Impact factor: 3.402
Authors: Jennifer R Kramer; Lori A Fischbach; Peter Richardson; Abeer Alsarraj; Stephanie Fitzgerald; Yasser Shaib; Neena S Abraham; Maria Velez; Rhonda Cole; Bhupinderjit Anand; Gordana Verstovsek; Massimo Rugge; Paola Parente; David Y Graham; Hashem B El-Serag Journal: Clin Gastroenterol Hepatol Date: 2012-12-04 Impact factor: 11.382
Authors: Ai Kubo; Michael Blaise Cook; Nicholas J Shaheen; Thomas L Vaughan; David C Whiteman; Liam Murray; Douglas A Corley Journal: Gut Date: 2013-01-26 Impact factor: 23.059
Authors: Tarek Sawas; Sarah Killcoyne; Prasad G Iyer; Kenneth K Wang; Thomas C Smyrk; John B Kisiel; Yi Qin; David A Ahlquist; Anil K Rustgi; Rui J Costa; Moritz Gerstung; Rebecca C Fitzgerald; David A Katzka Journal: Gastroenterology Date: 2018-08-27 Impact factor: 22.682
Authors: Mohamed N Rafat; Hosni Abd-ElKareem Younus; Mohamed S El-Shorpagy; Mahmoud Haddad Hemida; Mohamed S El Shahawy; Ahmed Abd El Aziz El Sayed Atiia Journal: JGH Open Date: 2018-01-28